mexacarbate: insecticide & acaricide; minor descriptor (75-82); online & Index Medicus search INSECTICIDES, CARBAMATE (75-82)
ID Source | ID |
---|---|
PubMed CID | 9414 |
CHEMBL ID | 454804 |
CHEBI ID | 82092 |
SCHEMBL ID | 121459 |
MeSH ID | M0262440 |
Synonym |
---|
phenol, 4-(dimethylamino)-3,5-dimethyl-, methylcarbamate (ester) |
mexacarbate |
315-18-4 |
4-(dimethylamino)-3,5-dimethylphenyl methylcarbamate |
carbamate, 4-dimethylamino-3,5-xylyl n-methyl- |
einecs 206-249-3 |
nci-c00544 |
4-(dimethylamino)-3,5-xylyl methylcarbamate |
methyl-4-dimethylamino-3,5-xylyl carbamate |
4-(dimethylamine)-3,5-xylyl n-methylcarbamate |
oms 639 |
caswell no. 579b |
zectran |
ai3-25766 |
4-(dimethylamino)-3,5-dimethylphenol methylcarbamate (ester) |
carbamic acid, methyl-, 4-(dimethylamino)-3,5-dimethylphenyl ester |
mexicarbate |
methyl-4-dimethylamino-3,5-xylyl ester of carbamic acid |
dowco 139 |
zectrane |
hsdb 1042 |
methylcarbamic acid, 4-(dimethylamino)-3,5-xylyl ester |
mexacarbate [ansi] |
brn 2216978 |
4-(dimethylamino)-3,5-dimethylphenyl n-methylcarbamate |
3,5-dimethyl-4-(dimethylamino)phenyl methylcarbamate |
zectane |
3,5-xylenol, 4-(dimethylamino)-, methylcarbamate |
4-dimethylamino-3,5-xylyl n-methylcarbamate |
4-dimethylamino-3,5-xylyl methylcarbamate |
epa pesticide chemical code 044201 |
zextran |
ent 25766 |
ccris 411 |
carbamic acid, methyl-, 4-(dimethylamino)-3,5-xylyl ester |
4-dimethylamino-3,5-xylyl-n-methylcarbamate |
oms-47 |
4-(n,n-dimethylamino)-3,5-xylyl n-methylcarbamate |
4-(dimethylamino)-3,5-xylenol, methylcarbamate (ester) |
carbamic acid, methyl-, 4-dimethylamino-3,5-xylyl ester |
MAZ , |
[4-(dimethylamino)-3,5-dimethylphenyl] n-methylcarbamate |
chebi:82092 , |
CHEMBL454804 |
NCGC00248781-01 |
C18952 |
dtxcid50893 |
cas-315-18-4 |
tox21_200649 |
dtxsid7020893 , |
NCGC00258203-01 |
mexacarbate [ansi:iso] |
unii-ztm4ipv8g8 |
ztm4ipv8g8 , |
mexacarbate [mi] |
mexacarbate [iso] |
zectran [iarc] |
phenol, 4-(dimethylamino)-3,5-dimethyl-, 1-(n-methylcarbamate) |
methylcarbamic acid 4-(dimethylamino)-3,5-xylyl ester |
mexacarbate [hsdb] |
SCHEMBL121459 |
4-(dimethylamino)-3,5-xylenol, methylcarbamate |
4-(dimethylamino)-3,5-dimethylphenyl methylcarbamate # |
ent 25,766 |
phenol, 4-(dimethylamino)-3,5-dimethyl-, methylcarbamate |
4-(dimethylamino)-3,5-dimethylphenol methylcarbamate |
4-dimethylamino-3,5-dimethylphenyl n-methylcarbamate |
carbamic acid, 3,5-dimethyl-4-dimethylaminophenyl ester, n-methyl |
mexacarbate, pestanal(r), analytical standard |
pesticide9_mexacarbate_c12h18n2o2_4-(dimethylamino)-3,5-dimethylphenyl methylcarbamate |
Q6825702 |
Excerpt | Relevance | Reference |
---|---|---|
"Zectran (4-dimethylamino-3,5-xylyl N-methyl-carbamate), a carbamate insecticide (active ingredient [AI] mexacarbate), was aerially applied to two 300 ha plots of coniferous forest at dosage rates of 70 and 140 g AI/ha, respectively." | ( An interlaboratory comparison of data on brain cholinesterase activity in forest songbirds exposed to aerial application of Zectran. Busby, DG; Fleming, RA; Holmes, SB, 1992) | 0.5 |
Class | Description |
---|---|
benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 4.5491 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 27.8722 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 57.1851 | 0.0002 | 21.2231 | 8,912.5098 | AID1259381; AID743042; AID743054 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 34.3762 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 18.4876 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 42.4517 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 30.6379 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 5.4981 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 60.0123 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 64.7528 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID399286 | In vivo inhibition of acetylcholinesterase from nerve tissue of Lymnaea acuminata at 2.5 mg/L relative to control | |||
AID399292 | Inhibition of acetylcholinesterase from nerve tissue of Lymnaea acuminata at 1 ug w/v relative to control | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (66.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.86) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |